Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 10, 2005, Pages 1033-1040

  Sugimoto, M ^a   Furuta, T ^a   Shirai, N ^a   Nakamura, A ^a   Kajimura, M ^a   Sugimura, H ^a   Hishida, A ^a   Ishizaki, T ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 2C19; PEPSINOGEN I; PEPSINOGEN II;

ADULT; AGED; ARTICLE; ATROPHY; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTRITIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER;

AGED; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; STOMACH NEOPLASMS;

EID: 27744469450     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02678.x     Document Type: Article

References (40)

1. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
2. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201.
3. Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-71.
4. Furuta T, Shirai N, Takashima M, Xiao F, Sugimura H. Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori. Am J Med 2002; 112: 141-3.
5. Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol 2004; 39: 220-30.
6. Park GT, Lee OY, Kwon SJ, et al. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J Gastroenterol Hepatol 2003; 18: 1257-63.
7. Tsukino H, Kuroda Y, Qiu D, Nakao H, Imai H, Katoh T. Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int J Cancer 2002; 100: 425-8.
8. Gao C, Takezaki T, Wu J, et al. Interaction between cytochrome P-450 2E1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiol Biomarkers Prev 2002; 11: 29-34.
9. Cai L, Yu SZ, Zhan ZF. Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle, Fujian Province. World J Gastroenterol 2001; 7: 792-5.
10. Yokose T, Doy M, Kakiki M, Horie T, Matsuzaki Y, Mukai K. Expression of cytochrome P450 3A4 in foveolar epithelium with intestinal metaplasia of the human stomach. Jpn J Cancer Res 1998; 89: 1028-32.
11. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212.
12. Sugimoto M, Furuta T, Shirai N, et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to CYP2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301.
13. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37.
14. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995; 58: 155-64.
15. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181-202.
16. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). Oncol Rep 2003; 10: 1615-23.
17. Kamataki T, Fujita K, Nakayama K, Yamazaki Y, Miyamoto M, Ariyoshi N. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab Rev 2002; 34: 667-76.
18. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004; 5: 211-24.
19. Tsuneoka Y, Fukushima K, Matsuo Y, Ichikawa Y, Watanabe Y. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci 1996; 59: 1711-5.
20. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol 2004; 10: 1961-3.
21. Chau TK, Marakami S, Kawai B, Nasu K, Kubota T, Ohnishi A. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Life Sci 2000; 67: 1719-24.
22. Plebani M. Pepsinogens in health and disease. Crit Rev Clin Lab Sci 1993; 30: 273-328.
23. Miki K, Ichinose M, Ishikawa KB, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993; 84: 1086-90.
24. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
25. Furuta T, Kaneko E, Baba S, Arai H, Futami H. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am J Gastroenterol 1997; 92: 84-8.
26. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
27. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6.
28. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
29. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
30. Furuta T, Shirai N, Xiao F, et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2004; 2: 22-30.
31. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
32. Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis 2000; 21: 387-95.
33. Wu AH, Yang D, Pike MC. A meta-analysis of soyfoods and risk of stomach cancer: the problem of potential confounders. Cancer Epidemiol Biomarkers Prev 2000; 9: 1051-8.
34. Sugiyama A, Maruta F, Ikeno T, et al. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998; 58: 2067-9.
35. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 1998; 115: 642-8.
36. Nagao M, Sugimura T. Carcinogenic factors in food with relevance to colon cancer development. Mutat Res 1993; 290: 43-51.
37. Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16: 214-5.
38. Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ. Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999; 48: 402-8.
39. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281: 604-9.
40. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.